[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634344":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":47,"collaborators":25,"id":49,"slug":25,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":25,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":25,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":52,"conditions":64,"keywords":25,"overallStatus":66,"whyStopped":25,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A (RT)","EXPERIMENTAL","Period 1 : Reference Drug(AD-1231 and AD-1232), Period 2 : Test Drug(AD-123)",[13,14],"Drug: AD-123","Drug: AD-1231 and AD-1232",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B (TR)","Period 1 : Test Drug(AD-123), Period 2 : Reference Drug(AD-1231 and AD-1232)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-123","AD-123 Oral Tablet",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-1231 and AD-1232","AD-1231 Oral Tablet + AD-1232 Oral Tablet",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Dasom Kim","CONTACT","+82-31-891-5572","dskim@addpharma.co.kr",[37],{"facility":38,"status":25,"city":39,"state":25,"zip":25,"country":40,"countryCode":25,"cosmosGeoPoint":41,"geoPoint":46,"contacts":25},"H Plus Yangji Hospita","Seoul","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.9784,37.566,{"lat":45,"lon":44},{"type":48,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100634344",false,"NCT07538466","A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 in Healthy Adult Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":59,"type":60},50,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1",[65],"Diabetes Mellitus","NOT_YET_RECRUITING","2026-04-12",{"date":69,"type":70},"2026-04-20","ACTUAL",{"date":72,"type":60},"2026-04",{"date":74,"type":60},"2026-05",{"name":5,"class":6},1]